MX2023000448A - Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta. - Google Patents

Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta.

Info

Publication number
MX2023000448A
MX2023000448A MX2023000448A MX2023000448A MX2023000448A MX 2023000448 A MX2023000448 A MX 2023000448A MX 2023000448 A MX2023000448 A MX 2023000448A MX 2023000448 A MX2023000448 A MX 2023000448A MX 2023000448 A MX2023000448 A MX 2023000448A
Authority
MX
Mexico
Prior art keywords
antibodies
delta
gamma
cell receptors
bind psma
Prior art date
Application number
MX2023000448A
Other languages
English (en)
Inventor
Hulsik David Lutje
Der Vliet Johannes Jelle Van
Robertus Cornelis Roovers
Paul Willem Henri Ida Parren
Lisa Anna King
Iglesias Victoria Guimarais
Peter Alexander Gerardus Maria Machielsen
Original Assignee
Lava Therapeutics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics N V filed Critical Lava Therapeutics N V
Publication of MX2023000448A publication Critical patent/MX2023000448A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a anticuerpos capaces de unirse a PSMA humano y capaces de unirse al receptor de células T V?9V?2 humana; la invención se refiere además a composiciones farmacéuticas que comprenden los anticuerpos de la invención y a usos de los anticuerpos de la invención para tratamiento médico.
MX2023000448A 2020-07-08 2021-07-08 Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta. MX2023000448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20184800 2020-07-08
PCT/EP2021/068960 WO2022008646A1 (en) 2020-07-08 2021-07-08 Antibodies that bind psma and gamma-delta t cell receptors

Publications (1)

Publication Number Publication Date
MX2023000448A true MX2023000448A (es) 2023-04-20

Family

ID=71527722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000448A MX2023000448A (es) 2020-07-08 2021-07-08 Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta.

Country Status (11)

Country Link
US (1) US20230272110A1 (es)
EP (1) EP4178981A1 (es)
JP (1) JP2023532807A (es)
KR (1) KR20230042035A (es)
CN (1) CN116323667A (es)
AU (1) AU2021305396A1 (es)
BR (1) BR112023000269A2 (es)
CA (1) CA3188601A1 (es)
IL (1) IL299748A (es)
MX (1) MX2023000448A (es)
WO (1) WO2022008646A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2023250485A1 (en) * 2022-06-23 2023-12-28 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
BRPI0619056A2 (pt) 2005-11-28 2011-09-20 Genmab As anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
US20120134993A1 (en) 2009-03-27 2012-05-31 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CA2892193C (en) 2012-11-21 2018-06-19 Pharmabcine Inc. Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same
WO2015156673A1 (en) 2014-04-10 2015-10-15 Stichting Vu-Vumc IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
BR112019010602A2 (pt) * 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
CN111448212A (zh) * 2017-09-14 2020-07-24 戴纳立制药公司 抗trem2抗体及其使用方法

Also Published As

Publication number Publication date
IL299748A (en) 2023-03-01
BR112023000269A2 (pt) 2023-03-28
CN116323667A (zh) 2023-06-23
EP4178981A1 (en) 2023-05-17
US20230272110A1 (en) 2023-08-31
JP2023532807A (ja) 2023-07-31
AU2021305396A1 (en) 2023-02-09
CA3188601A1 (en) 2022-01-13
KR20230042035A (ko) 2023-03-27
WO2022008646A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
MX2023000448A (es) Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta.
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12017502358A1 (en) Factor xi antibodies and methods of use
MX2019009358A (es) Anticuerpo anti-gprc5d y molecula que comprende el anticuerpo.
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
MX2023006832A (es) Anticuerpos que se unen a receptores de linfocitos t gamma-delta.
NZ756763A (en) Engineered transferrin receptor binding polypeptides
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
PH12019501387A1 (en) Anti-cd3 antibody and molecules comprising the antibody
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
EA201390813A1 (ru) Антитела и их применение
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
MY170404A (en) Antigen binding proteins
MX2021005085A (es) Formulacion de anticuerpo.
MA44917A1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
CR20230259A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
PH12021551174A1 (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
EA202192488A1 (ru) Антитела против tsg-6 и их применения
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).